```json
{
"content": [
{
"type": "paragraph",
"content": "North America dominates the Newborn Screening Program market, commanding 42% share. Mandatory-state policies, 99% hospital birth coverage, and CMS reimbursement sustain ecosystem maturity; venture into AI-powered metabolic panels secures regional forecast CAGR of 6.8%."
},
{
"type": "paragraph",
"content": "Europe ranks second, propelled by the EU Rare Disease Strategy that mandates ≥29-disorder panels, €150m Horizon Europe investments, and centralised procurement. Nordic digital registries and Germany’s Genetic Diagnostics Act accelerate adoption; expect Newborn Screening Program market growth at 7.2% CAGR."
},
{
"type": "paragraph",
"content": "Asia Pacific is the fastest-growing region (9.1% CAGR). Government-led universal screening initiatives in China and India, 18m annual births, and ¥2.5bn public-private infrastructure funds offset fragmented systems; regional forecast sees revenues doubling by 2029."
},
{
"type": "paragraph",
content: "Latin America advances through national neonatal networks—Brazil’s Portaria 3.§/2022 screens 98% of 2.8m newborns—while PAHO bulk-procurement lowers reagent cost 18%. Donor-backed PPPs and demographic tailwinds underpin 8.0% CAGR."
},
{
"type": "paragraph",
content: "Middle East & Africa prioritises high-burden metabolic disorders; Saudi Arabia’s 22-disorder panel and UAE genomics fund signal intent. Limited labs create opportunities for decentralised DBS testing and mobile units, sustaining 7.5% regional forecast CAGR."
}
],
"worldMapData": {
"regions": [
{ "name": "North America", "value": 42 },
{ "name": "Europe", "value": 28 },
{ "name": "Asia Pacific", "value": 18 },
{ "name": "Latin America", "value": 8 },
{ "name": "Middle East & Africa", "value": 4 }
]
}
}
```
